The most-cited NMN trial enrolled only women. It reported one clear result — improved muscle insulin sensitivity in overweight postmenopausal women with prediabetes — and it did not measure energy, skin, or menopause symptoms. For women buying NMN in the US, that is stronger evidence than this category usually offers, and narrower than the marketing suggests.
Most supplement categories fail women the same way: the research is run in men, and the label is written for everyone. NMN is the rare exception, and it is worth understanding precisely — because the trial that put NMN on the map studied women exclusively, and what it found is not what NMN is usually sold for.
The Single Most-Cited NMN Trial Enrolled Women Only
The paper that anchors nearly every NMN discussion is a 2021 randomised, placebo-controlled trial published in Science. Its title states the population outright: "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women" (Yoshino et al., Science, 2021).
Every participant was a woman. They were postmenopausal, overweight or obese, and had prediabetes. They took 250 mg of NMN daily for ten weeks.
This is unusual enough to state plainly. In most supplement categories a woman reading the evidence is reading about men and hoping it transfers. Here the flagship efficacy result came from a female-only cohort. The catch is not who was studied — it is what was studied.
What It Measured Was Insulin Sensitivity, Not Energy
The trial's endpoint was insulin-stimulated glucose disposal, measured with a hyperinsulinaemic-euglycaemic clamp — the reference laboratory method for insulin sensitivity. That number improved on NMN and did not change on placebo. Muscle insulin signalling moved alongside it.
That is a real, carefully measured metabolic finding. It is also not the reason most women put NMN in a shopping cart. Nobody in that trial was asked whether they felt more energetic, slept better, thought more clearly, or looked younger. Those outcomes were not endpoints, so the study cannot speak to them in either direction.
The distinction matters because it changes who the result applies to. The women in the trial had prediabetes and carried excess weight — a group whose insulin sensitivity had measurable room to improve. A metabolically healthy 52-year-old buying NMN for morning energy is not that population, and no trial has tested her.
Improved muscle insulin sensitivity is a laboratory measurement, not a feeling. It is entirely possible for that number to move while nothing about your day changes.
The Same Trial Did Not Detect a Rise in NAD+
This is the finding that sits most awkwardly beside the advertising, and the paper says it directly: a change in NAD+ content was not detected (Yoshino et al., Science, 2021).
Read that against the standard pitch. NMN is sold almost entirely on a single mechanism — it is a precursor to NAD+, NAD+ declines with age, therefore taking NMN restores it. In the trial where the clinical outcome actually improved, the mechanism everybody advertises was not the thing the researchers could measure moving in muscle tissue.
Other trials have raised NAD+ in blood. A 12-week placebo-controlled trial in 30 volunteers taking 250 mg daily reported increased blood NAD+ with no abnormalities in physiological or laboratory tests (Okabe et al., Frontiers in Nutrition, 2022). A separate 12-week trial split 250 mg into two 125 mg capsules across 36 healthy middle-aged participants and found serum nicotinamide significantly higher than placebo, with arterial stiffness trending down but missing statistical significance (Katayoshi et al., Scientific Reports, 2023).
So blood NAD+ responds. Whether that translates into anything you would notice is a separate question, and a woman deciding what to buy deserves to know those are two different claims rather than one.
The Safety Ladder Underneath It Starts With Ten Men
The female-only flagship has a male-only bookend, and it is the first rung of the safety evidence. The earliest human NMN study gave single doses of 100, 250 and 500 mg on separate days with five hours of monitoring afterwards. Heart rate, blood pressure, oxygen saturation and body temperature did not move, and lab shifts stayed inside normal reference ranges. Its title is equally explicit about who took part: "healthy Japanese men" (Irie et al., Endocrine Journal, 2020).
The larger safety work since then has been mixed-sex. A 60-day dose-ranging trial randomised 80 healthy middle-aged adults to placebo, 300, 600 or 900 mg daily; all 80 completed it with no safety issues across adverse-event monitoring, labs and clinical measures (Yi et al., GeroScience, 2023). And a four-week study of 1,250 mg once daily in 31 adults aged 20 to 65 — a paper whose title specifies "healthy adult men and women" — reported no severe adverse events and no changes beyond normal physiological variation (Fukamizu et al., Scientific Reports, 2022).
Women are represented in the safety record. What no published trial has done is report female-specific safety outcomes separately.
Four Things Nobody Has Measured in Women
The honest inventory of what is missing is short and specific:
✅ Menopause symptoms — no trial has tracked hot flushes, night sweats, sleep disruption or mood on NMN
✅ Hormones — no published study reports estrogen, progesterone or any sex-hormone outcome
✅ Fertility and the menstrual cycle — not an endpoint in any human NMN trial
✅ Pregnancy and breastfeeding — no human safety data exists, so the answer is to skip it
The postmenopausal framing of the Science trial makes the first gap especially easy to misread. A study can enrol postmenopausal women without studying menopause. That trial recruited postmenopausal women because it was investigating metabolic health in a group with prediabetes — not because it was testing anything about the menopause transition.
If a product page or an ad implies NMN does something for menopause symptoms, that claim is not coming from this evidence base. For the hormone-adjacent questions, take them to your own clinician rather than to a label.
The Dose the Trials Used, and What to Check on a US Label
The female-only trial used 250 mg a day. So did the two 12-week trials that raised NAD+ markers. Higher doses have been tested for safety and for blood NAD+, with the 60-day ladder finding 600 mg and 900 mg raised NAD+ furthest without a matching jump in safety problems. Our full breakdown of how much NMN per day the trials actually used walks the whole ladder rather than repeating it here.
Three things are worth checking on any US label before you buy:
- The serving size in milligrams, printed on the panel. If a page advertises a benefit but does not print how many milligrams are in a serving, you cannot compare it to a trial dose at all.
- Whether methyl support is included. NMN metabolism consumes methyl groups, which is the reasoning behind pairing it with TMG — covered in our guide to why NMN and TMG are paired.
- Servings per container, not just capsule count. A bottle of 60 capsules at two capsules a day is a 30-day supply, and that is what decides your real monthly cost.
Timing is a smaller question than dose, and we have covered it separately in when to take NMN. Tolerability and drug-interaction checks live in our NMN side effects guide.
The Trials, by Who Was Actually in Them
| Trial | Daily dose | Who took part | Length | What it reported |
|---|---|---|---|---|
| Yoshino 2021, Science | 250 mg | Postmenopausal women with prediabetes, overweight or obese — women only | 10 weeks | Muscle insulin sensitivity improved; NAD+ change not detected |
| Irie 2020, Endocrine Journal | 100 / 250 / 500 mg, single doses | 10 healthy men — men only | One day each | No symptom or vital-sign change; lab shifts within normal range |
| Okabe 2022, Frontiers in Nutrition | 250 mg | 30 volunteers, mixed | 12 weeks | Blood NAD+ up; no physiological or lab abnormalities |
| Katayoshi 2023, Scientific Reports | 250 mg (2 × 125 mg) | 36 healthy middle-aged adults, mixed | 12 weeks | Serum nicotinamide up; arterial stiffness trended down, not significant |
| Yi 2023, GeroScience | 300 / 600 / 900 mg | 80 healthy middle-aged adults, mixed | 60 days | NAD+ rose with dose; all 80 completed, no safety issues |
| Fukamizu 2022, Scientific Reports | 1,250 mg | 31 adults aged 20–65, men and women | 4 weeks | Safety endpoints only; no severe adverse events |
OUR VERDICT
A woman considering NMN has better direct evidence than most supplement categories offer — one placebo-controlled trial run entirely in women, with a laboratory-grade endpoint that moved. She also has zero evidence on menopause symptoms, hormones, fertility or pregnancy, and should treat any claim in those areas as unsupported.
Where This Leaves a Woman Buying NMN in the US
Buy it for what it has been shown to do, at a dose a trial actually used, and check the panel before you pay. Wellness Nest ships the AgeAura line across the United States, and the AgeAura NMN + TMG NAD+ Complex is $69.95; across the AgeAura collection the NMN + TMG range runs from $59.95 to $159.99 depending on format and size. Compare the milligrams and the servings per container across those options rather than the sticker price alone.
Two honest limits before you decide. The strongest efficacy result came from women with prediabetes who were overweight — if that is not you, the trial does not tell you what will happen. And the improvement was a metabolic laboratory measurement, not a change in how anybody reported feeling.
If you are weighing NMN against something with a broader evidence base for women in midlife, creatine is the better-studied comparison, and we have written about what changes for women over 40 separately. Other options for this life stage sit in the Women's Essentials collection and our best sellers.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. If you take prescription medication, are pregnant or breastfeeding, or manage a diagnosed metabolic condition, speak with your own clinician before starting NMN.
See the full ingredient panel →
Frequently Asked Questions
Does NMN work for women?
One placebo-controlled trial run entirely in women reported a clear result: 250 mg of NMN daily for ten weeks improved muscle insulin sensitivity in overweight postmenopausal women with prediabetes, measured with a hyperinsulinaemic-euglycaemic clamp. That is the strongest female-specific evidence in this category. It does not extend to energy, skin, cognition or sleep, because that trial did not measure them.
Is NMN safe for women?
The safety record includes women, though no trial reports female-specific safety separately. A four-week study of 1,250 mg daily in 31 adults described as healthy men and women found no severe adverse events, and a 60-day trial of up to 900 mg daily in 80 middle-aged adults was completed by all 80 participants with no safety issues. Anyone on prescription medication should still check with a clinician first.
Does NMN help with menopause symptoms?
No trial has tested it. This is a common misreading of the evidence, because the best-known NMN trial enrolled postmenopausal women — but it recruited them to study metabolic health in prediabetes, not to study the menopause transition. Hot flushes, night sweats, sleep disruption and mood were not endpoints in any published NMN study.
Can I take NMN while pregnant or breastfeeding?
No. There is no human safety data for NMN in pregnancy or lactation, so there is nothing to base a decision on. Skip it, and take the question to your own clinician.
How much NMN should a woman take?
The trial conducted in women used 250 mg a day, and two other 12-week trials that raised NAD+ markers used the same amount. Higher doses of 300 to 900 mg have been tested in mixed-sex groups and raised blood NAD+ further. Start from what was actually studied rather than from the biggest number on a label.
Where can I buy NMN for women in the US?
Wellness Nest ships the AgeAura NMN + TMG NAD+ Complex across the United States at $69.95, with the wider NMN + TMG range running $59.95 to $159.99. Buy from a store that prints the serving size and the servings per container on the page, so you can line the dose up against the trials before you pay.
About the Author
Dr. Marcus Hale — Dr. Marcus Hale is the resident health researcher behind Wellness Nest's editorial team, translating peer-reviewed sports-nutrition and longevity research into practical daily guidance for US readers.
